LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Company’s vCLAS™ Cryoablation System. The study, which seeks to enroll 206 patients with either ischemic or non-ischemic
Related Questions
What were the key financial metrics (revenue, net loss, cash burn) reported for Q2 2025?
When is the company expecting to complete the FULCRUM-VT study and submit data to the FDA?
What are the implications of the FULCRUM-VT study results for the commercial launch of the vCLAS™ Cryoablation System?
Did Adagio provide any updated guidance or outlook for the remainder of 2025?
How does Adagio's current cash position and runway compare to its burn rate and upcoming capital needs?
What competitive pressures exist in the catheter ablation market, and how might this study affect Adagio's market share?
Are there any partnership or licensing agreements in place that could be impacted by the study results?
What is the expected pricing and reimbursement landscape for the vCLAS™ Cryoablation System upon launch?
How might the market react to the enrollment milestone and any potential data readout from the pivotal study?
How does the 85% enrollment progress in the FULCRUM-VT pivotal study compare to the company's projected timelines?